In a world first, an Australian cancer support app will integrate into a hospital electronic medical record, providing patient symptom and activity data for clinicians to view remotely and in real time.
CancerAid, the leading cancer support app in Australia, the US and the UK, has developed ClinicianLink, which will link into the Epic EMR at prestigious US hospital Cedars-Sinai.
The major contract has come about as a result of CancerAid’s participation in the Techstars and Cedars-Sinai healthcare accelerator and follows a $1 million capital raise to drive CancerAid’s expansion in the US.
CancerAid allows patients to access medically reliable cancer information, log their symptoms, medications, treatments and activity, and join a community of more than 20,000 users worldwide using the app.
“Integrating into the healthcare providers’ workflow is crucial when you’re trying to improve clinical practice in digital health,” CancerAid Chief Technology Officer Andrew Harvey said.
“I’m incredibly proud of our team and the way they have been able to work closely with Cedars-Sinai clinicians to build an integration which provides clinical users with this vital insight. Integrating into a large health system can be difficult and our product team have done a wonderful job of navigating those challenges.”
Vice President for Service Line Operations at Cedars-Sinai Joan August said the “thoroughly impressive” CancerAid integration is a way to meet the hospital’s goals.
“Improving the patient experience and reducing hospital costs are key to what we are trying to achieve at Cedars-Sinai Hospital,” she said.
“CancerAid offers a thoroughly impressive way to address these goals and it is encouraging to see to that many of our patients are already using the app. With CancerAid, we are now able to provide a 21st Century solution to help achieve our goals.”
Results from a randomised clinical trial presented at the 2017 American Society of Clinical Oncology annual meeting revealed that patients who used a symptom tracking system were able to achieve improved clinical outcomes with improved management of symptoms, better patient quality of life and fewer visits to emergency departments. The study claimed an average survival benefit of five months.
The CancerAid app is now commercially available for hospitals, insurers and pharmaceutical companies, with more than 80 US hospitals signed up. It remains free for patients and caregivers.
It is ranked in the top 200 medical apps in the Apple App and Google Play stores, out of 96,000 currently on the market.
At the Talent Unleashed Awards 2017, CancerAid was awarded Best Start-up and Best Start-up Creating Social Impact in the APAC Global region by a judging panel including Steve Wozniak, the co-founder of Apple, and Sir Richard Branson of Virgin Group.